Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy (Review)

Yao,Kui; Bian,Ce; Zhao,Xia

doi:10.3892/etm.2017.4642

Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy (Review)

Authors:
- Kui Yao
- Ce Bian
- Xia Zhao
View Affiliations

Affiliations: Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, P.R. China
Published online on: June 22, 2017 https://doi.org/10.3892/etm.2017.4642
Pages: 1271-1276
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS) affects 5-20% of the reproductive age women globally. PCOS is diagnosed by the presence of hyperandrogenism, oligo-anovulation, and polycystic morphology of at least one ovary. Insulin resistance (IR), hyperinsulinemia and associated metabolic abnormalities including metabolic syndrome play a significant role in the development of PCOS. The chances of developing MS in PCOS women was shown to increase by almost 14-fold in patients with increasing body mass index. Even in the absence of overt obesity, a preferential deposition of intra-abdominal fat is noted in PCOS women and this intra‑abdominal fat leads to impaired insulin action and functional IR and hyperandrogenism. Functional ovarian hyperandrogenism of ovaries was suggested to be a consequence of IR, which activates androgen synthesizing enzyme, cytochrome p450‑c17α‑hydroxylase, in ovarian theca cells and causes elevated oxidative stress accompanied by lower antioxidant status in ovaries, which contribute to PCOS pathogenesis. The elevated levels of luteinizing hormone that accompany the early stages of hyperandrogenemia, accelerate ovarian functional deterioration, which is further aggravated by hyperinsulinemia, in PCOS women. The risk of developing gestational diabetes in PCOS women is approximately three times greater, as compared to non-PCOS women, due to IR and hyperinsulinemia. Typical insulin‑sensitizing drugs such as metformin, have been used to curtail IR and hyperinsulinemia in pregnant PCOS women, with varying results indicating the complexity of the disease and the need for better controlled studies and additional efforts for PCOS‑specific drug discovery.

View Figures

View References

1	Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ and Yildiz BO: Polycystic ovary syndrome. Nat Rev Dis Primers. 2:160572016. View Article : Google Scholar : PubMed/NCBI
2	Amato MC, Vesco R, Vigneri E, Ciresi A and Giordano C: Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. J Endocrinol Invest. 38:1319–1326. 2015. View Article : Google Scholar : PubMed/NCBI
3	Diamanti-Kandarakis E and Dunaif A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 33:981–1030. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ford ES: The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 173:309–314. 2004. View Article : Google Scholar : PubMed/NCBI
5	Polak K, Czyzyk A, Simoncini T and Meczekalski B: New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 40:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
6	Kauffman RP, Baker VM, DiMarino P and Castracane VD: Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome. Fertil Steril. 85:1010–1016. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al: Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 97:28–38.e25. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS and Ghazzi MN; PCOS/Troglitazone Study Group, : Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 91:48–53. 2006. View Article : Google Scholar : PubMed/NCBI
9	Bhattacharya SM: Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol. 26:516–520. 2010. View Article : Google Scholar : PubMed/NCBI
10	Soares EM, Azevedo GD, Gadelha RG, Lemos TM and Maranhão TM: Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril. 89:649–655. 2008. View Article : Google Scholar : PubMed/NCBI
11	Madani T, Hosseini R, Ramezanali F, Khalili G, Jahangiri N, Ahmadi J, Rastegar F and Zolfaghari Z: Metabolic syndrome in infertile women with polycystic ovarian syndrome. Arch Endocrinol Metab. 60:199–204. 2016. View Article : Google Scholar : PubMed/NCBI
12	Vural B, Caliskan E, Turkoz E, Kilic T and Demirci A: Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod. 20:2409–2413. 2005. View Article : Google Scholar : PubMed/NCBI
13	Carmina E, Napoli N, Longo RA, Rini GB and Lobo RA: Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 154:141–145. 2006. View Article : Google Scholar : PubMed/NCBI
14	Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF and Teede HJ: Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 28:777–784. 2013. View Article : Google Scholar : PubMed/NCBI
15	Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall'Alda M, et al: Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 98:E628–E637. 2013. View Article : Google Scholar : PubMed/NCBI
16	Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS and Legro RS: Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 36:487–525. 2015. View Article : Google Scholar : PubMed/NCBI
17	Baptiste CG, Battista MC, Trottier A and Baillargeon JP: Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 122:42–52. 2010. View Article : Google Scholar : PubMed/NCBI
18	Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, Thomas AM, Grogan TR, Haykal R, Schooler TA, et al: Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 101:4178–4188. 2016. View Article : Google Scholar : PubMed/NCBI
19	de Zegher F, Lopez-Bermejo A and Ibáñez L: Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol Metab. 20:418–423. 2009. View Article : Google Scholar : PubMed/NCBI
20	Unger RH, Clark GO, Scherer PE and Orci L: Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 1801:209–214. 2010. View Article : Google Scholar : PubMed/NCBI
21	Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, Hellström M, Lönn L, Olivecrona G, Stener-Victorin E, et al: Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 96:E304–E311. 2011. View Article : Google Scholar : PubMed/NCBI
22	Rosenfield RL, Ehrlich EN and Cleary RE: Adrenal and ovarian contributions to the elevated free plasma androgen levels in hirsute women. J Clin Endocrinol Metab. 34:92–98. 1972. View Article : Google Scholar : PubMed/NCBI
23	Futterweit W and Deligdisch L: Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab. 62:16–21. 1986. View Article : Google Scholar : PubMed/NCBI
24	Dunaif A, Segal KR, Futterweit W and Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1165–1174. 1989. View Article : Google Scholar : PubMed/NCBI
25	Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW and Ryan KJ: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 62:904–910. 1986. View Article : Google Scholar : PubMed/NCBI
26	Cara JF and Rosenfield RL: Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 123:733–739. 1988. View Article : Google Scholar : PubMed/NCBI
27	Rosenfield RL, Barnes RB, Cara JF and Lucky AW: Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril. 53:785–791. 1990. View Article : Google Scholar : PubMed/NCBI
28	Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF and Sheikh Z: Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 327:157–162. 1992. View Article : Google Scholar : PubMed/NCBI
29	González F, Rote NS, Minium J and Kirwan JP: Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 91:336–340. 2006. View Article : Google Scholar : PubMed/NCBI
30	Suresh S and Vijayakumar T: Correlations of insulin resistance and serum testosterone levels with LH:FSH ratio and oxidative stress in women with functional ovarian hyperandrogenism. Indian J Clin Biochem. 30:345–350. 2015. View Article : Google Scholar : PubMed/NCBI
31	Nisenblat V and Norman RJ: Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 16:224–231. 2009. View Article : Google Scholar : PubMed/NCBI
32	Rosenfield RL and Ehrmann DA: The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of pcos as functional ovarian hyperandrogenism revisited. Endocr Rev. 37:467–520. 2016. View Article : Google Scholar : PubMed/NCBI
33	Azziz R: Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 83:1343–1346. 2005. View Article : Google Scholar : PubMed/NCBI
34	Rodrigues JK, Navarro PA, Zelinski MB, Stouffer RL and Xu J: Direct actions of androgens on the survival, growth and secretion of steroids and anti-Müllerian hormone by individual macaque follicles during three-dimensional culture. Hum Reprod. 30:664–674. 2015. View Article : Google Scholar : PubMed/NCBI
35	Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al: Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society: The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 91:456–488. 2009. View Article : Google Scholar : PubMed/NCBI
36	Homburg R: Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab. 20:281–292. 2006. View Article : Google Scholar : PubMed/NCBI
37	Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G and Abyholm T: Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest. 54:94–98. 2002. View Article : Google Scholar : PubMed/NCBI
38	Weerakiet S, Srisombut C, Rojanasakul A, Panburana P, Thakkinstian A and Herabutya Y: Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome. Gynecol Endocrinol. 19:134–140. 2004. View Article : Google Scholar : PubMed/NCBI
39	Anttila L, Karjala K, Penttilä RA, Ruutiainen K and Ekblad U: Polycystic ovaries in women with gestational diabetes. Obstet Gynecol. 92:13–16. 1998. View Article : Google Scholar : PubMed/NCBI
40	Turhan NO, Seçkin NC, Aybar F and Inegöl I: Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynaecol Obstet. 81:163–168. 2003. View Article : Google Scholar : PubMed/NCBI
41	Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD and Chen HY: Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 11:562013. View Article : Google Scholar : PubMed/NCBI
42	Glueck CJ, Wang P, Goldenberg N and Sieve-Smith L: Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 17:2858–2864. 2002. View Article : Google Scholar : PubMed/NCBI
43	Glueck CJ, Wang P, Kobayashi S, Phillips H and Sieve-Smith L: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 77:520–525. 2002. View Article : Google Scholar : PubMed/NCBI
44	Ghazeeri GS, Nassar AH, Younes Z and Awwad JT: Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstet Gynecol Scand. 91:658–678. 2012. View Article : Google Scholar : PubMed/NCBI
45	Nawaz FH, Khalid R, Naru T and Rizvi J: Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res. 34:832–837. 2008. View Article : Google Scholar : PubMed/NCBI
46	Costello MF and Eden JA: A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 79:1–13. 2003. View Article : Google Scholar : PubMed/NCBI
47	Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA and Nestler JE: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 87:524–529. 2002. View Article : Google Scholar : PubMed/NCBI
48	Ben-Haroush A, Yogev Y and Hod M: Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabet Med. 21:103–113. 2004. View Article : Google Scholar : PubMed/NCBI
49	Eckel RH, Grundy SM and Zimmet PZ: The metabolic syndrome. Lancet. 365:1415–1428. 2005. View Article : Google Scholar : PubMed/NCBI
50	Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A, Guzick DS and Hoeger KM: Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 93:4780–4786. 2008. View Article : Google Scholar : PubMed/NCBI
51	Apridonidze T, Essah PA, Iuorno MJ and Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 90:1929–1935. 2005. View Article : Google Scholar : PubMed/NCBI
52	Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E and Dilbaz S: Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obstet Gynaecol Res. 42:837–843. 2016. View Article : Google Scholar : PubMed/NCBI
53	Abruzzese GA, Cerrrone GE, Gamez JM, Graffigna MN, Belli S, Lioy G, Mormandi E, Otero P, Levalle OA and Motta AB: Lipid accumulation product (LAP) and visceral adiposity index (VAI) as markers of insulin resistance and metabolic associated disturbances in young argentine women with polycystic ovary syndrome. Horm Metab Res. 49:23–29. 2016. View Article : Google Scholar : PubMed/NCBI
54	Turkmen S, Ahangari A and Bäckstrom T: Roux-en-y gastric bypass surgery in patients with polycystic ovary syndrome and metabolic syndrome. Obes Surg. 26:111–118. 2016. View Article : Google Scholar : PubMed/NCBI
55	Legro RS, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Fleming J, Allison KC, et al: Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab. 100:4048–4058. 2015. View Article : Google Scholar : PubMed/NCBI
56	Colilla S, Cox NJ and Ehrmann DA: Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 86:2027–2031. 2001. View Article : Google Scholar : PubMed/NCBI
57	Wu S, Divall S, Nwaopara A, Radovick S, Wondisford F, Ko C and Wolfe A: Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 63:1270–1282. 2014. View Article : Google Scholar : PubMed/NCBI
58	Codner E and Escobar-Morreale HF: Clinical review: hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 92:1209–1216. 2007. View Article : Google Scholar : PubMed/NCBI
59	Facchinetti F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, Di Renzo GC, Hod M, Cavalli P, Chiu TT, et al: Results from the International Consensus Conference on myo-inositol and d-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 195:72–76. 2015. View Article : Google Scholar : PubMed/NCBI
60	Ehrmann DA, Breda E, Corcoran MC, Cavaghan MK, Imperial J, Toffolo G, Cobelli C and Polonsky KS: Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 287:E241–E246. 2004. View Article : Google Scholar : PubMed/NCBI